A Comparison Between Patients with Gastrointestinal Stromal Tumours Diagnosed with Isolated Liver Metastases and Liver Metastases Plus Sarcomatosis

Overview

Journal HPB (Oxford)

Publisher Elsevier

Specialty Gastroenterology

Date 2013 Mar 6

PMID 23458233

Citations 2

Authors

Sebastian G de la Fuente

Jeremiah L Deneve

Colin M Parsons

Jonathan S Zager

Anthony P Conley

Ricardo J Gonzalez

Affiliations

Soon will be listed here.

Abstract

Objectives: This study was conducted to compare overall survival (OS) in patients presenting with isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and sarcomatosis on a background of gastrointestinal stromal tumours (GISTs).

Methods: Patients presenting with metastatic GISTs during 1999-2009 were identified. Survival outcomes were compared between groups.

Results: Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16 presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620).

Conclusions: Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease burden might be expected to show worse survival, these data do not reflect this assumption.

Citing Articles

Management of liver metastases from gastrointestinal stromal tumors: where do we stand?.

Machairas N, Prodromidou A, Molmenti E, Kostakis I, Sotiropoulos G J Gastrointest Oncol. 2018; 8(6):1100-1108.

PMID: 29299371 PMC: 5750192. DOI: 10.21037/jgo.2017.08.08.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor.

Bryan M, Fitzgerald N, Levine E, Shen P, Stewart J, Votanopoulos K Am Surg. 2014; 80(9):890-5.

PMID: 25197876 PMC: 4208104.

References

Sym S, Ryu M, Lee J, Chang H, Kim T, Kim H . Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008; 98(1):27-33. DOI: 10.1002/jso.21065. View

Pisters P, Blanke C, von Mehren M, Picus J, Sirulnik A, Stealey E . A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol. 2011; 22(11):2523-2529. DOI: 10.1093/annonc/mdq773. View

Turley R, Peng P, Reddy S, Barbas A, Geller D, Marsh J . Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 2011; 118(14):3571-8. PMC: 3290751. DOI: 10.1002/cncr.26650. View

Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali P . Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. Ann Oncol. 2009; 21(2):403-408. DOI: 10.1093/annonc/mdp310. View

Benjamin R, Debiec-Rychter M, Cesne A, Sleijfer S, Demetri G, Joensuu H . Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol. 2009; 36(4):302-11. DOI: 10.1053/j.seminoncol.2009.06.003. View

Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T . Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol. 2007; 12(3):212-7. DOI: 10.1007/s10147-007-0657-y. View

Cirocchi R, Farinella E, La Mura F, Cavaliere D, Avenia N, Verdecchia G . Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review. Tumori. 2010; 96(3):392-9. DOI: 10.1177/030089161009600303. View

Meza J, Wong S . Surgical options for advanced/metastatic gastrointestinal stromal tumors. Curr Probl Cancer. 2011; 35(5):283-93. DOI: 10.1016/j.currproblcancer.2011.09.003. View

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G . Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002; 8(10):3034-8. View

10.

Demetri G, von Mehren M, Antonescu C, DeMatteo R, Ganjoo K, Maki R . NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010; 8 Suppl 2:S1-41. PMC: 4103754. DOI: 10.6004/jnccn.2010.0116. View

11.

Kobayashi K, Gupta S, Trent J, Vauthey J, Krishnamurthy S, Ensor J . Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer. 2006; 107(12):2833-41. DOI: 10.1002/cncr.22336. View

12.

Demetri G, von Mehren M, Blanke C, Van Den Abbeele A, Eisenberg B, Roberts P . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7):472-80. DOI: 10.1056/NEJMoa020461. View

13.

Joensuu H, Eriksson M, Hall K, Hartmann J, Pink D, Schutte J . One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12):1265-72. DOI: 10.1001/jama.2012.347. View

14.

Kobayashi K, Szklaruk J, Trent J, Ensor J, Ahrar K, Wallace M . Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Am J Clin Oncol. 2009; 32(6):574-81. DOI: 10.1097/COC.0b013e31819cca35. View

15.

Jones R, McCall J, Adam A, ODonnell D, Ashley S, Al-Muderis O . Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol. 2010; 36(5):477-82. DOI: 10.1016/j.ejso.2009.12.005. View

16.

Heinrich M, Corless C, Blanke C, Demetri G, Joensuu H, Roberts P . Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006; 24(29):4764-74. DOI: 10.1200/JCO.2006.06.2265. View

17.

Zalcberg J, Verweij J, Casali P, Cesne A, Reichardt P, Blay J . Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005; 41(12):1751-7. DOI: 10.1016/j.ejca.2005.04.034. View

18.

Kim E, Zalupski M . Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol. 2011; 104(8):901-6. DOI: 10.1002/jso.21872. View

19.

Caram M, Schuetze S . Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J Surg Oncol. 2011; 104(8):888-95. DOI: 10.1002/jso.21930. View

20.

DeMatteo R, Maki R, Singer S, Gonen M, Brennan M, Antonescu C . Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007; 245(3):347-52. PMC: 1877004. DOI: 10.1097/01.sla.0000236630.93587.59. View